Stock comparison
Haemonetics
TransMedics Group
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
TMDX
TransMedics Group
Market cap
$2.38B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | TMDX | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 55D | HAE |
| Benjamin Graham | 85A | 61D | HAE |
| Philip Fisher | 60C | 56C | HAE |
| Peter Lynch | 54C | 84C | TMDX |
| Joel Greenblatt | 31F | 48D | TMDX |
| Charlie Munger | 54D | 54D | Tie |
| Terry Smith | 55D | 47D | HAE |
Side-by-side metrics
| Metric | HAE | TMDX |
|---|---|---|
| Market cap | $2.98B | $2.38B |
| P/E (TTM) | 24.8x | 12.6x |
| EV/EBIT | 14.1x | 23.4x |
| ROIC (TTM) | 8.37% | 6.94% |
| Gross margin | 55.74% | 59.09% |
| Net margin | 7.29% | 27.04% |
| Revenue CAGR 5y | 7.65% | 111.5% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 1.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 23.4x+40%
- Market cap$2.98Bvs $2.38B+20%
- ROIC (TTM)8.37%vs 6.94%+17%
- Debt / Equity1.5xvs 1.7x+7%
TMDX leads on
- Revenue CAGR 5y111.5%vs 7.65%+93%
- Net margin27.04%vs 7.29%+73%
- P/E (TTM)12.6xvs 24.8x+49%
- Gross margin59.09%vs 55.74%+6%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.